2014-广泛小细胞肺癌化疗后胸部放疗研究-CREST TRAIL.pdf

Articles Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial Ben J Slotman, Harm van Tinteren, John O Praag, Joost L Knegjens, Sherif Y El Sharouni, Matthew Hatton, Astrid Keijser, Corinne Faivre-Finn*, Suresh Senan* Summary Lancet 2015; 385: 36–42 Background Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and Published Online prophylactic cranial irradiation, have persistent intrathoracic disease. We assessed thoracic radiotherapy for treatment September 14, 2014 of this patient group. /10.1016/ S0140-6736(14)61085-0 Methods We did this phase 3 randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 in the UK, three in This online publication has been corrected. The corrected Norway, and one in Belgium. We enrolled patients with WHO performance score 0–2 and con? rmed ES-SCLC who version ? rst appeared at responded to chemotherapy. They were randomly assigned (1:1) to receive either thoracic radiotherapy (30 Gy in on ten fractions) or no thoracic radiotherapy. All underwent prophylactic cranial irradiation. The primary endpoint was September 25, 2014, the overall survival at 1 year in the intention-to-treat population. Secondary endpoints included progression-free survival. second corrected version appeared on This study is registered with the Nederlands Trial Register, number NTR1527. November 18, 2014 See Comment page 9 Findings We randomly assigned 498 patients between Feb 18, 2009, and Dec 21, 2012. Three withdrew informed *Contributed equally consent, leaving 247 patients in the thoracic radiotherapy group and 248 in the control group. Mean interval between Department of Radiation diagnosis and